ISRCTN61514736 https://doi.org/10.1186/ISRCTN61514736

The effect of PRIME-MD on the detection and referral-for-treatment of occult psychiatric treatment in the Emergency Department (ED).

Submission date
17/02/2005

Recruitment status
No longer recruiting

Registration date
21/02/2005

Overall study status
Completed

Last Edited
03/08/2007

Condition category
Mental and Behavioural Disorders

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[X] Results
[ ] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr David Schriger

Contact details
924 Westwood Blvd Suite 300
Los Angeles, CA
United States of America
90024-2924
+1 310 794 0593
schriger@ucla.edu

Additional identifiers

Study information

Scientific Title

Acronym
UCLA PRIME MD-2

Study objectives
Not provided at time of registration.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration.

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Diagnostic

Health condition(s) or problem(s) studied
Depression, anxiety and other psychiatric conditions

Interventions
Patients take the computerized PRIME-MD in the ED waiting room. They are randomized to three groups: PRIME-MD results shared with no one, shared with the patient only, or shared with the patient and the treating ED physician.
Low cost/no cost psychiatric referral sheet made available in the ED.

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Not provided at time of registration.

Key secondary outcome(s))
Not provided at time of registration.

Completion date
01/09/2002

Eligibility

Key inclusion criteria
ED patients who present with a somatic (non-psychiatric) complaint that is of long duration, is chronic, or is not of a severity to warrant emergency care.
Resident physicians in Emergency Medicine and their faculty.

Participant type(s)

Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Not Specified

Key exclusion criteria
Not provided at time of registration.

Date of first enrolment
01/03/2002

Date of final enrolment
01/09/2002

Locations

Countries of recruitment
United States of America

Study participating centre
924 Westwood Blvd Suite 300
Los Angeles, CA
United States of America
90024-2924

Sponsor information

Organisation
University of California, Los Angeles (UCLA) (USA)

ROR
https://ror.org/046rm7j60

Funder(s)

Funder type
Industry

Funder Name
The Pfizer Corporation provided a $60,000 gift (not grant) in support of this research.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	09/05/2005		Yes	No